Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a

Blood

Volumn 122, Issue 6, 2013, Pages 893-901

  Quintás Cardama, Alfonso ^a   Abdel Wahab, Omar ^b   Manshouri, Taghi ^a   Kilpivaara, Outi ^b,c   Cortes, Jorge ^a   Roupie, Anne Laure ^b   Zhang, Su Jiang ^d   Harris, David ^a   Estrov, Zeev ^a   Kantarjian, Hagop ^a   Levine, Ross L ^b   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; DNA METHYLTRANSFERASE 3A; HYDROXYUREA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; PEGINTERFERON ALPHA2A; STEROID; TRANSCRIPTION FACTOR EZH2; ALPHA INTERFERON; DNA BINDING PROTEIN; JAK2 PROTEIN, HUMAN; MACROGOL DERIVATIVE; ONCOPROTEIN; RECOMBINANT PROTEIN; TET2 PROTEIN, HUMAN;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLELE; ANEMIA; ARTICLE; CENTRAL PONTINE MYELINOLYSIS; CEREBROVASCULAR ACCIDENT; CLONAL EVOLUTION; COHORT ANALYSIS; COLONY FORMATION; DEPRESSION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; EPIGENETICS; EYE TOXICITY; FATIGUE; FOLLOW UP; HUMAN; HYPONATREMIA; INFECTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MUTATION RATE; MYELOFIBROSIS; NEUROPATHY; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THROMBOCYTHEMIA; TRAFFIC ACCIDENT; TREATMENT RESPONSE; FEMALE; GENETIC EPIGENESIS; GENETICS; GENOTYPE; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTERFERON-ALPHA; JANUS KINASE 2; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RECOMBINANT PROTEINS; REMISSION INDUCTION; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883185991     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-442012     Document Type: Article

References (37)

1. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
2. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4): 387-397.
5. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788-22792.
6. Hino M, Futami E, Okuno S, Miki T, Nishizawa Y, Morii H. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol. 1993;66(3): 161-162.
7. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101(8):3294-3301.
8. Massaro P, Foa P, Pomati M, et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol. 1997;56(2):126-128.
9. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8): 3065-3072.
10. Kiladjian JJ, Massé A, Cassinat B, et al; French Intergroup of Myeloproliferative Neoplasms (FIM). Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24(8):1519-1523.
11. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32): 5418-5424.
12. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011; 118(7):1723-1735.
13. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24.
14. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012;44(1):23-31.
15. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25-38.
16. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17):4509-4518.
17. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
18. Talpaz M, Rakhit A, Rittweger K, et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res. 2005;11(17): 6247-6255.
19. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5): 459-468.
20. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32.e1-32.e9.
21. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-2040.
22. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-4833.
23. Dean FB, Hosono S, Fang L, et al. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci USA. 2002;99(8):5261-5266.
24. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089.
25. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147.
26. Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol. 2011;18(2): 117-123.
27. Tefferi A. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia. 2011;25(7):1059-1063.
28. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
29. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24(7):1302-1309.
30. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5): 905-911.
31. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011; 25(7):1200-1202.
32. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-726.
33. Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011; 25(7):1219-1220.
34. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25(7):1217-1219.
35. Turlure P, Cambier N, Roussel M, et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a (peg-IFNα-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial [abstract]. Blood. 2011; 118(21). Abstract 280.
36. Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA. 2011; 108(35):14566-14571.
37. Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012;488(7413):656-659.